---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-050005"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2024-12-20T23:59:59+00:00"
generated_at: "2026-05-29T00:03:46.992961+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Galectin NAVIGATE trial: belapectin reduces varices by 48.9% in per-protocol but misses ITT primary endpoint

## Summary
- In ITT (N=355), primary composite endpoint not statistically significant; varices incidence reduced 43.2% with 2mg/kg vs placebo.
- In per-protocol (n=290), belapectin 2mg/kg showed 48.9% reduction in varices (p<0.05).
- Safety profile favorable; adverse events comparable across cohorts, no drug-related SAEs.
- Additional 36-month data from ~50 patients expected in Q1 2025.
- Company will engage with potential partners to determine next steps.

## SEC filing metadata
- accession: 0001140361-24-050005
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2024-12-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036124050005/0001140361-24-050005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036124050005/ef20040433_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-050005
- JSON: https://secwatch.observer/filing/0001140361-24-050005.json
- Plain text: https://secwatch.observer/filing/0001140361-24-050005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.